
### **Amendments to the Claims**

The following listing of claims will replace all prior versions and listings of claims in the application.

# **Listing of Claims:**


1. (Currently amended) A compound for modulating c-Kit activity according to Formula I,



or a pharmaceutically acceptable salt, thereof, wherein,

ring A is:

	(R <sup>1</sup> ) <sub>0-3</sub>	
X	$ \left\langle \frac{Z}{\frac{\parallel}{\parallel}} \right\rangle \\ \left\langle R^{1}\right\rangle_{0-2} $	$(R^1)_{0-1}$
(R <sup>1</sup> ) <sub>0-1</sub>	N \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Z N II (R <sup>1</sup> ) <sub>0-1</sub>
(R <sup>1</sup> ) <sub>0-4</sub>	$(R^1)_{0-5}$ $Z$ $Z$ $Y$ $Y$	(R <sup>1</sup> ) <sub>0-5</sub> Y



- wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and- $N(R^7)$ -, provided that the A ring contains at least one annular N, O, or S;
- each  $R^1$  is independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>4</sup>, -S(O)<sub>0-2</sub>R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, -NCO<sub>2</sub>R<sup>4</sup>, -C(=O)R<sup>4</sup>, optionally substituted alkoxy, optionally substituted  $C_{1-6}$ alkyl, optionally substituted aryl  $C_{1-6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1-6}$ alkyl;
- two adjacent of  $R^1$ , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of  $R^{10}$ ;

L<sup>1</sup> is a single bond;

ring B is phenyl;

- each  $R^2$  is independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -S(O)<sub>0-2</sub>R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, -NCO<sub>2</sub>R<sup>4</sup>, -C(=O)R<sup>4</sup>, optionally substituted alkoxy, optionally substituted  $C_{1-6}$ alkyl, optionally substituted aryl, optionally substituted heterocyclyl  $C_{1-6}$ alkyl;
- two adjacent of  $R^2$ , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of  $R^{15}$ ;
- $L^2$  is selected from -N(H)N(H)C(=O)N(H)-, -CH<sub>2</sub>N(H)C(=O)N(H)-, -CH<sub>2</sub>OC(=O)N(H)-, and -XCH<sub>2</sub>C(=O)N(H)-; wherein X is selected from -O-, -S(O)<sub>0-2</sub>-, and -N(R<sup>7</sup>)-; and any C-H of  $L^2$  is optionally C-R<sup>20</sup>;

ring C is phenyl;

- each R³ is independently selected from halogen, trihalomethyl, -CN,-NO<sub>2</sub>, -OR⁴, -N(R⁴)R⁴, -S(O)<sub>0-2</sub>R⁴, -SO<sub>2</sub>N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)SO<sub>2</sub>R⁴, -N(R⁴)C(O)R⁴, -NCO<sub>2</sub>R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C<sub>1-6</sub>alkyl, optionally substituted aryl, optionally substituted aryl C<sub>1-6</sub>alkyl, optionally substituted heterocyclyl C<sub>1-6</sub>alkyl; provided R³ is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide, wherein there exists at least one of R³ that is halogen or trihalomethyl;
- $R^4$  is selected from -H, optionally substituted  $C_{1\text{-}6}$ alkyl, optionally substituted aryl, optionally substituted aryl  $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl  $C_{1\text{-}6}$ alkyl;
- two of R<sup>4</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- $R^5$  is selected from -H, -CN, -NO<sub>2</sub>, -OR<sup>4</sup>, -S(O)<sub>0-2</sub>R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, optionally substituted  $C_{1\text{-}6}$ alkyl, optionally substituted  $C_{1\text{-}6}$ alkenyl, and optionally substituted  $C_{1\text{-}6}$ alkynyl;
- $R^7$  is selected from -H, optionally substituted  $C_{1\text{-}6}$ alkyl, -SO<sub>2</sub>N( $R^4$ ) $R^4$ , -CO<sub>2</sub> $R^4$ , -C(=O)N( $R^4$ ) $R^4$ , -C(=N $R^5$ )N( $R^4$ ) $R^4$ , -C(=N $R^5$ ) $R^4$ , -C(=O) $R^4$ , optionally substituted aryl  $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1\text{-}6}$ alkyl; and
- each of  $R^{10}$ , each of  $R^{15}$ , each of  $R^{20}$ , and each of  $R^{25}$  is independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -S(O)<sub>0-2</sub>R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, -NCO<sub>2</sub>R<sup>4</sup>, -C(=O)R<sup>4</sup>, optionally substituted alkoxy, optionally substituted  $C_{1-6}$ alkyl, optionally substituted aryl, optionally substituted aryl

312-913-0001

 $C_{1-6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1-6}$ alkyl;

### provided:

the compound is not one of:

N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide,

N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide,

N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide

2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl]acetamide

2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-(trifluoromethyl)phenyl]acetamide

N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide or

N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

#### 2-12. (Cancelled)

- 13. (Canceled)
- 14. (Original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical meta- to  $L^2$ .
- 15. (Previously presented) The compound according to claim 1, wherein each of  $R^3$  is independently selected from halogen, trihalomethyl,  $-OR^4$ ,  $-C(=O)R^4$ , and optionally substituted  $C_{1-6}$ alkyl.
- 16. (Currently amended) A compound for modulating c-Kit activity according to the following Formula:

or a pharmaceutically acceptable salt, thereof, wherein,

## W is selected from the following:

	(R <sup>27</sup> ) <sub>0-3</sub>	
Z	$Z = \frac{1}{11}$ $(R^{27})_{0-2}$	$(R^{27})_{0-1}$
(R <sup>27</sup> ) <sub>0-1</sub>	$ \begin{array}{c c}  & Z & \\ \hline  &   & \\  &   & \\  &   & \\  &   & \\  &   &   & \\  &   &   & \\  &   &   & \\  &   &   &   & \\  &   &   &   & \\  &   &   &   & \\  &   &   &   & \\  &   &   &   & \\  &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   & \\  &   &   &   &   &   &   & \\  &   &   &   &   &   &   & \\  &   &   &   &   &   &   & \\  &   &   &   &   &   &   &   & \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   \\  &   &   &   &   &   &   &   &   &   & $	Z N
(R <sup>27</sup> ) <sub>0-4</sub> Y Y	$(R^{27})_{0-5}$	(R <sup>27</sup> ) <sub>0-5</sub> Y Y Y
(R <sup>27</sup> ) <sub>0-6</sub> Y Y Y Y Y Y	(R <sup>27</sup> ) <sub>0-6</sub>	$(R^{27})_{0-6} \xrightarrow{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{}}$

each of  $R^{27}$  independently selected from halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>55</sup>, -S(O)<sub>0-2</sub>R<sup>55</sup>, -SO<sub>2</sub>N(R<sup>55</sup>)R<sup>55</sup>, -C(=O)N(R<sup>55</sup>)R<sup>55</sup>, -C(=NR<sup>50</sup>)N(R<sup>55</sup>)R<sup>55</sup>, -C(=NR<sup>50</sup>)R<sup>55</sup>, -N(R<sup>55</sup>)SO<sub>2</sub>R<sup>55</sup>, -N(R<sup>55</sup>)C(O)R<sup>55</sup>, -NCO<sub>2</sub>R<sup>55</sup>, -C(=O)R<sup>55</sup>, optionally substituted alkoxy, optionally substituted  $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1\text{-}6}$ alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O) $_{0-2}$ -, and -N(R $^7$ )-,

provided that the W ring contains at least one annular annular N, O, or S;

E and G are each independently selected from -O-, -S(O)<sub>0-2</sub>-, -C(R<sup>31</sup>)R<sup>32</sup>-, and -N(R<sup>33</sup>)-;  $J_1$  and  $J_2$  are each independently =C(H)- or =N-;

- $R^{26}$  is independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>40</sup>, -N(R<sup>40</sup>)R<sup>40</sup>, -S(O)<sub>0-2</sub>R<sup>40</sup>, -SO<sub>2</sub>N(R<sup>40</sup>)R<sup>40</sup>, -CO<sub>2</sub>R<sup>40</sup>, -C(=O)N(R<sup>40</sup>)R<sup>40</sup>, -C(=NR<sup>50</sup>)N(R<sup>40</sup>)R<sup>40</sup>, -C(=NR<sup>50</sup>)R<sup>40</sup>, -N(R<sup>40</sup>)SO<sub>2</sub>R<sup>40</sup>, -N(R<sup>40</sup>)C(O)R<sup>40</sup>, -NCO<sub>2</sub>R<sup>40</sup>, -C(=O)R<sup>40</sup>, optionally substituted alkoxy, optionally substituted  $C_{1-6}$ alkyl, optionally substituted aryl  $C_{1-6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1-6}$ alkyl;
- R<sup>30</sup> is independently selected from halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>40</sup>, -N(R<sup>40</sup>)R<sup>40</sup>, -S(O)<sub>0-2</sub>R<sup>40</sup>, -SO<sub>2</sub>N(R<sup>40</sup>)R<sup>40</sup>, -C(=O)N(R<sup>40</sup>)R<sup>40</sup>, -C(=NR<sup>50</sup>)N(R<sup>40</sup>)R<sup>40</sup>, -C(=NR<sup>50</sup>)N(R<sup>40</sup>)SO<sub>2</sub>R<sup>40</sup>, -N(R<sup>40</sup>)C(O)R<sup>40</sup>, -NCO<sub>2</sub>R<sup>40</sup>, -C(=O)R<sup>40</sup>, optionally substituted alkoxy, optionally substituted C<sub>1-6</sub>alkyl, optionally substituted aryl, optionally substituted aryl C<sub>1-6</sub>alkyl, optionally substituted heterocyclyl C<sub>1-6</sub>alkyl, wherein there exists at least one of R<sup>30</sup> that is trihalomethyl;
- $R^{31}$  and  $R^{32}$  are each independently selected from -H, halogen, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>40</sup>, -N(R<sup>40</sup>)R<sup>40</sup>, -S(O)<sub>0-2</sub>R<sup>40</sup>, -SO<sub>2</sub>N(R<sup>40</sup>)R<sup>40</sup>, -CO<sub>2</sub>R<sup>40</sup>, -C(=O)N(R<sup>40</sup>)R<sup>40</sup>, -C(=NR<sup>50</sup>)N(R<sup>40</sup>)R<sup>40</sup>, -C(=NR<sup>50</sup>)R<sup>40</sup>, -N(R<sup>40</sup>)SO<sub>2</sub>R<sup>40</sup>, -N(R<sup>40</sup>)C(O)R<sup>40</sup>, -NCO<sub>2</sub>R<sup>40</sup>, -C(=O)R<sup>40</sup>, optionally substituted alkoxy, optionally substituted  $C_{1-6}$ alkyl, optionally substituted aryl  $C_{1-6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1-6}$ alkyl;
- $R^{33}$  is selected from -H, optionally substituted lower alkyl,  $-SO_2N(R^{40})R^{40}$ ,  $-CO_2R^{40}$ ,  $-C(=O)N(R^{40})R^{40}$ ,  $-C(=NR^{50})N(R^{40})R^{40}$ ,  $-C(=NR^{50})R^{40}$ ,  $-C(=O)R^{40}$ , optionally substituted alkoxy, optionally substituted  $C_{1-6}$ alkyl, optionally substituted aryl, optionally substituted heterocyclyl  $C_{1-6}$ alkyl;

- $R^{40}$  is selected from -H, optionally substituted alkoxy, optionally substituted  $C_{1\text{-}6}$ alkyl, optionally substituted aryl, optionally substituted aryl  $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl  $C_{1\text{-}6}$ alkyl;
- two of R<sup>40</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- $R^{50}$  is selected from -H, -CN, -NO<sub>2</sub>, -OR<sup>40</sup>, -S(O)<sub>0-2</sub>R<sup>40</sup>, -CO<sub>2</sub>R<sup>40</sup>, optionally substituted  $C_{1-6}$ alkyl, optionally substituted  $C_{1-6}$ alkenyl, and optionally substituted  $C_{1-6}$ alkynyl;
- R<sup>55</sup> is selected from -H, optionally substituted C<sub>1-6</sub>alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C<sub>1-6</sub>alkyl; and
- two of R<sup>55</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.
- 17. (Cancelled)
- 18. (Currently amended) The compound according to claim 16, wherein R<sup>30</sup> is selected from halogen, trihalomethyl, -OR<sup>40</sup>, -N(R<sup>40</sup>)R<sup>40</sup>, -C(=O)R<sup>40</sup>, optionally substituted alkoxy, optionally substituted C<sub>1-6</sub>alkyl, optionally substituted aryl, optionally substituted aryl C<sub>1-6</sub>alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C<sub>1-6</sub>alkyl, wherein there exists at least one of R<sup>30</sup> that is trifluoromethyl.
- 19. (Cancelled)
- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Cancelled)

- 23. (Withdrawn) The compound according to claim 16, wherein E is selected from -O-,  $-S(O)_{0-2}$ -, and -NH-; and G is -CH<sub>2</sub>-.
- 24. (Withdrawn) The compound according to claim 16, wherein E is either -CH<sub>2</sub>- or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (Cancelled)
- 26. (Cancelled)
- 27. (Previously presented) A compound selected from the following Table:

Entry	Name	Structure
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH <sub>3</sub>
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N = N CI
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N=N CI
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N CH <sub>3</sub> CI

Entry	Name	Structure
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N ON NH
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	H F F F CI
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. O. N. F. CI
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. CH3
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N

Entry	Name	Structure
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N. N. P. P. F.
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N H F F F
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CH <sub>3</sub> H F F CI
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH <sub>3</sub> O N F F
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH <sub>3</sub> F Cl

Entry	Name	Structure
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N O O CH <sub>3</sub>
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N.O.N.F.F.F.F.F.F.F.F.F.F.F.F.F.F.F.
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N.
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H <sub>3</sub> C CI
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CI CI CI F F F

Entry	Name	Structure
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	S S S S S S S S S S S S S S S S S S S
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N. N. P. P. F.
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N CI F F
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CH <sub>3</sub> O CH <sub>3</sub> O F F F

Entry	Name	Structure
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N. N CH <sub>3</sub>
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N.N. P. F. F.
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-pyrrole-1- carboxylate	TO NOTE F
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	CI F F F
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	N O N F F

Entry	Name	Structure
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	F F F F F F F F F F F F F F F F F F F
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	ON PFFFF
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	$\begin{array}{c} O \\ O \\ N \\ H \end{array}$ $\begin{array}{c} CI \\ F \\ F \end{array}$ $\begin{array}{c} F \\ F \end{array}$
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	CO F F F F F F F F F F F F F F F F F F F
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N. N. H. N. H. F.

Entry	Name	Structure
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	H F F CI
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N N S N CI FFF
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	NN FFFF
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	N H F F
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N N N N F F

Entry	Name	Structure
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	NH PER
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	NH NH FFF
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N. N. H. F.
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	P F F F
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	N. N. N. H. N. F. F. F. F.

Entry	Name	Structure
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H <sub>3</sub> C CI F F F F
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	CI F F
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F CI F F F
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F

Entry	Name	Structure
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	ON H F F
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H <sub>3</sub> C <sub>2</sub> O <sub>N</sub> F <sub>F</sub> F <sub>F</sub>
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide	H <sub>3</sub> C <sub>2</sub> O N F F
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	ON PFFF
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H <sub>3</sub> C N H F F F

Entry	Name	Structure
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N CI F F F CH <sub>3</sub>
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	D N F F F
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (2,3,5,6-tetrafluoro-4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	F F F F F F F F F F F F F F F F F F F
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	ON PER F
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	N N N P F F

Entry	Name	Structure
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	ZH NH CO F F
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N N N N N N N N N N N N N N N N N N N
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CI FF F
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H <sub>3</sub> C.
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H <sub>3</sub> C N N F F

Entry	Name	Structure
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H <sub>3</sub> C <sup>-O</sup> N C F F F F
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H <sub>3</sub> C <sub>2</sub> O N N N N N N N N N N N N N N N N N N N
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H <sub>3</sub> C <sub>2</sub> O <sub>N</sub>
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	N=N HN.N
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N N F F
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N N N N N N N N N N N N N N N N N N N
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	H. N. N. P. F. F.

Entry	Name	Structure
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON FFFF
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON FFFF
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	ON FEFF
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	N N N F F
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	N N N N F F

Entry	Name	Structure
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	H N N H F F
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyrimidin-5-ylphenyl)methyl]urea	N H O CH <sub>3</sub>
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyridin-3-ylphenyl)methyl]urea	N N O CH3
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	CI O'CH <sub>3</sub>
130	(4-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	CI O'CH <sub>3</sub>

Entry	Name	Structure
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CH <sub>3</sub> O N F F F
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro- 3-(trifluoromethyl)phenyl]carbamate	CH <sub>3</sub> O CI F F F
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyridin-3-ylphenyl)methyl]urea	N O CH <sub>3</sub>
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyrimidin-5-ylphenyl)methyl]urea	N O CH <sub>3</sub>
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N O N CH <sub>3</sub>

Entry	Name	Structure
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N CH <sub>3</sub>
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	NH NH F
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH <sub>3</sub> O CI N N F F
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	CH <sub>3</sub> O CI F F F
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	ON H F F

Entry	Name	Structure
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	D N F F F
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	N N N N F F
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N CI F F F
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	CI F F
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	N N N N F F F

Entry	Name	Structure
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	N N N N N N N N N N N N N N N N N N N
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3- (1H-tetrazol-1-yl)phenyl]methyl}urea	N=N CI O-CH <sub>3</sub>
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N F F
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N N N N N N N N N N N N N N N N N N N
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N H H F F

Entry	Name	Structure
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N CI F F F
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H <sub>3</sub> C.O
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N H N F F F
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	CH <sub>3</sub>
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	H <sub>3</sub> C N

Entry	Name	Structure
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H <sub>3</sub> C CI F F F
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H <sub>3</sub> C CI
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F F
179	N-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H <sub>3</sub> C CF <sub>3</sub>
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	NC N O CI N N N CF3
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN P F F

Entry	Name	Structure
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	TZZ D C C C C C C C C C C C C C C C C C C C
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	S CH <sub>3</sub> CF <sub>3</sub>
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H <sub>3</sub> C N
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CI PFF F
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN F F F

Entry	Name	Structure
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH <sub>3</sub> ON N CI
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F F
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2-(methyloxy)phenyl]carbamate	CH <sub>3</sub> ON N CI
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N H CF <sub>3</sub>
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF <sub>3</sub>

Entry	Name	Structure
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN CF <sub>3</sub>
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CF <sub>3</sub> CI
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N CI ON CI CF <sub>3</sub>
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N CF3
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N F CF <sub>3</sub>

Entry	Name	Structure
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N N CF <sub>3</sub>
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	N.N.N.
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H <sub>3</sub> Cr <sup>S</sup> N CF <sub>3</sub>
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H <sub>3</sub> C CF <sub>3</sub>
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O CH <sub>3</sub> O N CI CF <sub>3</sub>

Entry	Name	Structure
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	N CF <sub>3</sub>
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	N N CF3
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	P CI F F F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HNN F

- 28. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
- 29. (Cancelled)
- 30. (Withdrawn) A method for modulating the *in-vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to claim 1.
- 31. (Withdrawn) The method according to claim 30, wherein the kinase is c-Kit.

- 32. (Withdrawn) The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.
- 33. (Withdrawn) A method of treating rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; artheroscrosis, myocardioinfarction, ischemia, stroke, restenosis; interbowel diseases, osteoarthritus, macular degeneration, or diabetic retinopathy, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in claim 1.
- 34. (Withdrawn) A method of screening for modulators of c-Kit, the method comprising combining the compound according to claim 1 and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.
- 35. (Withdrawn) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising the compound according to claim 1 to a cell or a plurality of cells.